E1 ReplicatedModerate confidencePEM unclearRCTPeer-reviewedMachine draft
Achieving symptom relief in patients with myalgic encephalomyelitis by targeting the neuro-immune interface and optimizing disease tolerance.
Rodriguez, Lucie, Pou, Christian, Lakshmikanth, Tadepally et al. · Oxford open immunology · 2023 · DOI
Quick Summary
Researchers tested whether gently stimulating nerve endings inside the nose could help ME/CFS patients feel better. After 8 weeks of treatment, patients showed about a 30% improvement in their overall symptoms. Blood tests showed that ME patients have signs of ongoing immune activation, and those who improved had changes in their immune cells and less inflammation.
Why It Matters
This study provides evidence that ME/CFS may respond to targeted neuro-immune interventions, offering hope for a treatment approach in a disease with very few proven therapies. The identification of immune signatures associated with clinical improvement could help researchers understand ME pathophysiology and develop more targeted interventions.
Observed Findings
- Approximately 30% reduction in overall symptom scores after 8 weeks of intranasal mechanical stimulation
- Chronic immune activation detected in blood samples from ME/CFS patients at baseline
- Increased gut-homing immune cells in patients who showed clinical improvement
- Reduced inflammation markers in treatment responders
- Upregulation of disease tolerance-related genes in patients with symptom relief
Inferred Conclusions
- Intranasal mechanical stimulation may produce symptom relief through activation of brainstem neuro-immune regulatory pathways
- ME/CFS may result from a maladaptive disease tolerance response triggered by prior infection
- Disease tolerance mechanisms rather than direct anti-inflammatory effects may underlie symptomatic improvement
- Blood-based immune signatures could potentially identify responders and biomarkers of treatment effectiveness
Remaining Questions
- What is the precise mechanism by which intranasal stimulation activates brainstem centers and produces clinical improvement?
- Why do only approximately 30% of treated patients show substantial symptom reduction, and can baseline immune or imaging markers predict treatment response?
What This Study Does Not Prove
This study does not prove that intranasal stimulation is a definitive cure or that it works equally well for all ME/CFS patients, as individual responses varied. It demonstrates correlation between immune changes and symptom improvement, but does not establish the precise mechanism by which nasal stimulation produces clinical benefit. The 30% improvement rate means 70% of patients did not show substantial improvement, and the study cannot explain why some patients respond and others do not.
Tags
Symptom:Post-Exertional MalaiseFatigueSensory Sensitivity
Biomarker:CytokinesGene ExpressionBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:Weak Case Definition
Metadata
- DOI
- 10.1093/oxfimm/iqad003
- PMID
- 37255930
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →